Antimicrobial resistance must be policy priority, say MPs

This article was taken from:

By Press Association at the Guardian

Global death toll from antimicrobial-resistant infections expected to rise to 10m a year by 2050

Tackling antimicrobial resistance needs to become a top-five policy priority for the government in order to help prevent the virtual loss of modern medicine, MPs have said.

A report by the health and social care committee said it wants to see “tangible progress” over the next six months to “reverse the worrying exodus” from research into antimicrobial resistance (AMR).

Antimicrobial-resistant infections kill at least 50,000 people a year in Europe and the US alone, and 700,000 people globally. These figures are predicted to rise dramatically over the next 30 years, with the death toll estimated to be 10 million a year by 2050 – higher than from cancer and diabetes combined.

Despite this, no new classes of antibiotics have been developed for decades. They are not seen as profitable by drug companies as new antibiotics are initially prescribed sparingly during their patent lives, rather than used as a first line treatment.

The report says that while in developed health systems it is possible to access alternative second- or third-line treatments when patients develop a resistant infection, mortality rates and costs of treatment are likely to be approximately double for a drug-resistant infection, generating an estimated cost to the NHS of £180m a year.

It said options to address this market failure include changes to patent law and to the ways that pharmaceutical companies are reimbursed for new antimicrobial medicines.

Although in primary care, there has been a 13% reduction in the number of prescriptions for antibiotics in the past five years, there has been less progress in secondary care and prescribing levels in the UK are still around double that of the Netherlands, Sweden and the Baltic states.

The report said a reduction in clinically unnecessary secondary-care prescribing was clearly needed. It also outlined that digital health tools for clinicians and policymakers could dramatically help to reduce the threat of antimicrobial resistance, but there has been significant variation in the uptake of this.

It suggested a single organisation be given responsibility for coordinating this across the NHS, and ensuring prompt evidence-based prescribing of antimicrobials, as well as other medicines.

The report said that, in terms of Brexit, the government must make a clear commitment that any future trade deals will require any meat and dairy produce imported into the UK to meet at least the same standards relating to antibiotic use that apply to meat and dairy products produced in the EU.

The committee chair, Dr Sarah Wollaston, said: “In six months we want to see tangible progress on implementing practical policies to reverse the worrying exodus from AMR research and development, and both government and industry should play their part in tackling this issue.”

Last month the committee heard that the problem had been a “top-five” issue under David Cameron’s government, but appeared to have become less important.

Lord O’Neill, who led a major review on the topic, told the committee he was not aware of any current senior ministers raising the issue.

A Department of Health and Social Care spokeswoman said: “The UK is a recognised global leader on AMR and we are committed to tackling the issue both at home and internationally.

“GPs already prescribe antibiotics 13% less than they did in 2013, we have invested record amounts in research and development, and we will set ourselves challenging ambitions for the next five years.”

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.



Our social media pages regularly provide useful company and industry updates.
Connect with us to stay informed!


©2024 OneCall24 - All Rights Reserved. Design & Build by Total Design Works Ltd.

Please contact us for our Terms & Conditions & FOI Act or click the following to view our privacy notice or cookie policy.